Curis to Present at Upcoming Healthcare Conferences in September
LEXINGTON, Mass., Sept. 6, 2023 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment...